Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADP-TILIL7 in Advanced Melanoma
NCT06204991Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Allogeneic CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous IL-7-expressing TILs in melanoma. Primary endpoints: Tolerability of the treatment at 1 year and Feasibility of the treatment at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
autologous IL-7-expressing TILs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06204991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204991.